Home > Selected Past Studies
SELECTED PAST STUDIES - ALL DISEASES
Study
Disease
type & number of samples
Specific Requirements
associated data required
HEM-1
Acute Myeloid Leukemia
Bone Marrow Mononuclear Cells
Retrospective
More than 20 subjects
- Relapsed or refractory AML patients
- 5-10 million BMMCs per subject
- Viably frozen
- Age, Gender, Ethnicity
- Medical history
- Diagnosis report
HEM-2
Acute Myeloid Leukemia
Whole Blood & PBMC
Prospective
More than 10 subjects
- Relapsed or refractory AML patients
- Samples collected before any treatment
- 20 ml whole blood collected on 3 different types of collecting tubes.
- PBMCs isolated right after blood collection and frozen at -80°C
- Blood Samples per patient must be shipped immediately after collection
- Age, Gender, Ethnicity
- Treatment history
- Diagnosis
HEM-3
Chronic Myeloid Leukemia
RNA
Retropective
More than 180 subjects treated by TKI
2 groups:
- 50% cases with an event (death, loss of Response, appearance of mutation…)
- 50% cases without an event (event-free at least 6 months after blood draw
- Subjects treated by Tyrosine Kinase Inhibitors treatment
- Demographic, diagnostic and medical data
- Confirmed diagnosis of BCR-ABL positive Chronic Myeloid Leukemia
- Treatment History and medical out-come
HEM-4
Diffuse Large B-Cell Lymphoma (DLBCL)
FFPE Blocks
Retrospective
More than 15 subjects
- Lymph node biopsy tissue blocks
- Subjects with newly diagnosed DLBCL
- Demographic, diagnostic and medical data
- Treatment History
HEM-5
Diffuse Large B Cell Lymphoma (DLBCL)
FFPE Blocks
Retrospective
More than 50 subjects
- Lymph node biopsy tissue blocks
- Relapsed and refractory DLBCL
- Last line of therapy must have been chemotherapy based regimen
- Age, Gender, Ethnicity
- Date of collection
- Clinical history
- Age, Gender, Ethnicity
- Date of collection
- Clinical history
- Pathology report
- Information about response to last line of therapy (response and progression free survival)
HEM-6
Peripheral T-Cell Lymphoma
FFPE Blocks
Retrospective
At least 20 subjects
- Lymph node biopsy tissue blocks from T-cell lymphomas:
- Cutaneous
- Angioimmunoblastic
- Extranodal natural killer/ T-cell lymphoma
- Nasal type
- Enteropathy type
- Subcutaneous panniculitis-like
- Anaplastic large cell lymphoma
- Age, Gender, Ethnicity
- Clinical history
- Pathology report
HEM-7
Mantle Cell Lymphoma
Peripheral Blood Mononuclear Cells and Isolated B-cells/Blasts
Retrospective
More than 10 subjects
- Newly diagnosed untreated patients
- Age, Gender, Ethnicity
- Sample collection date (year only)
- Clinical history
- Diagnosis report
HEM-8
T-Cell Lymphoma
FFPE Blocks
Retrospective
More than 60 subjects
6 groups:
- Adult T-Cell Leukemia/Lymphoma HTLV1+
- NK/T Lymphoma, nasal type
- Enteropathy-associated T Lymphoma
- Peripheral T-Cell Lymphoma
- T-Cell Lymphoma, NOS
- Angioimmunoblastic T-Cell Lymphoma
- Lymph nodes or biopsy tissue blocks
- Age, Gender, Ethnicity
- Medical history
- Diagnosis report
HEM-9
Lymphoma (Pediatric)
FFPE Blocks
Prospective
More than 25 subjects
- Lymph node biopsy or surgical resection tissue blocks
- Age, Gender, Ethnicity
- Sample collection date
- Confirmed Pathological diagnosis
- Date of initial diagnosis
HEM-10
ALK-positive Anaplastic Lymphoma
FFPE Blocks
Retrospective
More than 5 subjects
- ALK mutated
- Age, Gender, Ethnicity
- Pathological diagnosis
- Sample collection date
- Used method for detection of ALK rearrangements
HEM-11
Multiple Myeloma
Frozen Bone Marrow Biopsy
Prospective
More than 20 subjects
2 groups:
- Subjects with Relapsed or Refractory MM
- Newly diagnosed MM subjects, treatment naïve
- Patients under treatment at the time of collection
- Age, Gender, Ethnicity
- Sample collection date
- Confirmation of Diagnosis
- Treatment history
HEM-12
Multiple Myeloma
Frozen EDTA plasma-Red Blood Cell-lysed Bone Marrow Aspirate Cell Pellet-Bone Marrow FFPE Clot
Retrospective
More than 5 subjects
- Minimum of 0.5 mL of BMA to be used for cell pellet and FFPE clot samples
- Age, Gender, Ethnicity
- Clinical history
- Pathology report
GI-1
Colorectal Cancer
FFPE Blocks with Known KRAS Mutation Status and Matched Plasma
Prospective
More than 200 subjects
- Newly Diagnosed patients with Colorectal Cancer stage IV
- Blood samples collected before treatment
- Demographic, diagnostic and medical data
- Stage (TNM, grade)
- Treatment History and medical out-come
- KRAS mutation status
GI-2
Colorectal Cancer
FFPE Blocks with Known MMR Status
Retrospective
More than 70 subjects
- Known DNA mismatch repair (MMR) status
- Demographic, diagnostic and medical data
- Stage (TNM, grade)
GI-3
Colorectal Cancer
FFPE Blocks
Retrospective
More than 20 subjects
2 tissue samples per patient:
- One pre- treatment
- One post-treatment
- Demographic, diagnostic and medical data
- Stage (TNM, grade)
- Treatment History and medical out-come
GI-4
Colorectal Cancer
FFPE Blocks
Retrospective
More than 500 subjects
- Primary tumor
- Stage IIA or higher
- Surgery for primary colon cancer with a minimum of three years follow up, not treated with adjuvant chemotherapy
- Demographic, diagnostic and medical data
- Stage (TNM, grade)
- Treatment History and medical out-come
GI-5
Colorectal Cancer
FFPE slides
Retrospective
More than 60 subjects
- FFPE sections (10 slides of 10 μm) and one H&E stained slide
- Patients who underwent chemotherapy (surgery excluded): 50% responders & 50% non responders
- Samples collected before treatment
- Demographic, diagnostic and medical data
- Stage (TNM, grade)
- Treatment History and medical out-come
- Radiological data with tumor and metastases sizes before and after/during the treatment
GI-6
Colorectal Cancer
Freshly Resected Tumor Tissue
Prospective
5 subjects
- Adenocarcinoma
- Any stage
- Sample size: 2 g
- Samples must be received fresh within 48 hour of resection
- Demographic, diagnostic and medical data
- Stage (TNM, grade)
GI-7
Colorectal Cancer and Polyps
Serum
Retrospective
More than 60 subjects:
3 groups:
- Patients with Colorectal Cancer stage I & II
- Patients with Adenomatous Polyps
- Patients with Hyperplastic Polyps
- Group CRC: Samples collected before any treatment o surgery
- Group 2 & 3: Samples collected at time of colonoscopy
- Demographic, diagnostic and medical data
- Stage (TNM, grade)
GI-8
Colorectal Cancer
Serum
Prospective
More than 70 subjects
Patients treated with EGFR inhibitors:
- 50% patients with no adverse events
- 50% patients with diverse events
- Demographic, diagnostic and medical data
- Stage (TNM, grade)
- Date of treatment initiation
- Date and Description of adverse events
GI-9
Rectal Cancer
Serum
Retrospective
More than 100 subjects
- Locally Advanced Rectal Carcinoma (LARC), Stages II/III
- Samples collected before treatment
- Demographic, diagnostic and medical data
- Stage (TNM, grade)
- Treatment History and a 3 years medical out-come
GI-10
Gastric Cancer
FFPE Blocks and Matched PBMC
Retrospective
More than 50 subjects
- 2 groups: with or without relapse within 5 years
- Samples collected at diagnosis, before start of any treatment
- FFPE blocks must allow to cut at least 50 sections
- PBMC isolated from 10 mL of blood
- Demographic, diagnostic and medical data
- Stage (TNM, grade)
- Treatment History and medical out-come
- Biomarker status: EGFR, KRAS
GI-11
Gastric Cancer
Frozen Tissue
Retrospective
More than 50 subjects
- 2 samples per subject (greater than 0.5 gJ Gastric tumor and Normal Adjacent Tumor tissues
- Age, Gender, Ethnicity
- Sample collection date
- Weight, height, BMI
GI-12
Gastric Cancer
Whole Blood
Retrospective
More than 10 subjects
- Stage III or IV
- Samples collected from patients not under treatment: collected at time of diagnostic before any treatment
- Whole blood collected on specific preservative tubes
- Demographic, diagnostic and medical data
- Stage (TNM, grade)
GI-13
Adenocarcinoma of the Esophagogastric Junction
FFPE Blocks
Retrospective
More than 40 subjects
- Adenocarcinoma of the Esophagogastric Junction
- Stage IIIB or higher
- Demographic, diagnostic and medical data
- Stage (TNM, grade)
GI-14
Esophagus Carcinoma
FFPE Blocks
Retrospective
More than 160 subjects
2 groups:
- Adenocarcinomas
- Squamous Cell Carcinomas
- Stage III or higher
- Demographic, diagnostic and medical data
- Stage (TNM, grade)
- Treatment History
GI-15
Hepatocellular Carcinoma
Tissue Micro-Arrays
Retrospective
More than 180 subjects
- Patients newly diagnosed and treatment naïve
- All stages must be provided
- Demographic, diagnostic and medical data
- Stage (TNM, grade)
- Treatment History
GI-16
Liver Cancer
FFPE Blocks AND Matched Serum
Retrospective
More than 50 subjects
- Hepatocellular Carcinoma, Cholangiocarcinoma, metastatic adenocarcinoma or carcinoma…
- Demographic, diagnostic and medical data
- Stage (TNM, grade)
GI-17
Hepatocellular Carcinoma
FFPE Blocks
Retrospective
More than 200 subjects
- Asian patients only
- Child Pugh Score < or equal to 7 (one-year survival rate >80%)
- Demographic, diagnostic and medical data
- Stage (TNM, grade)
- Treatment History
- Child Pugh score
GI-18
Hepatocellular Carcinoma
FFPE Blocks with Matched PBMC
Retrospective
More than 40 subjects
- 2 groups: with or without relapse within 5 years
- Samples collected at diagnosis, before start of any treatment
- FFPE blocks must allow to cut at least 50 sections PBMC isolated from 10 mL of blood
- Demographic, diagnostic and medical data
- Stage (TNM, grade)
- Treatment History and medical out-come
GI-19
Hepatocellular Carcinoma
FFPE Slides
Retrospective
More than 20 subjects
- Asian patients only
- Primary HCC
- Demographic, diagnostic and medical data
- Stage (TNM, grade)
GI-20
Hepatocellular Carcinoma
FFPE Blocks and Matched Serum
Retrospective
More than 10 subjects
- Patients with primary Hepatocellular Carcinoma (HCC)
- Advanced stage/higher grade
- Demographic, diagnostic and medical data
- Stage (TNM, grade)
GI-21
Pancreatic Adenocarcinoma
Frozen Tissue and Matched Plasma
Retrospective
More than 20 subjects
- Any stage
- Frozen tissue of primary tumor
- Specimen collected at time of diagnosis
- Demographic, diagnostic and medical data
- Stage (TNM, grade)
- KRAS mutation status
GI-22
Pancreatic Adenocarcinoma
FFPE Blocks and Matched Serum
Retrospective
More than 50 subjects
- Pancreatic ductal adenocarcinoma
- Any stage
- Demographic, diagnostic and medical data
- Stage (TNM, grade)
GI-23
Neuroendocrine Pancreatic Cancer
FFPE Blocks
Retrospective
More than 20 subjects
- Pancreatic neuroendocrine tumor
- Advanced stages
- Demographic, diagnostic and medical data
- Stage (TNM, grade)
GI-24
Metastatic Pancreatic Cancer
FFPE Blocks
Retrospective
More than 30 subjects
- Metastatic pancreatic ductal adenocarcinoma
- Core needle biopsies of pancreatic ductal adenocarcinoma metastasis from liver
- Demographic, diagnostic and medical data
- Stage (TNM, grade)
GI-25
Pancreatic Cancer
Serum
Retrospective
More than 300 subjects
11 Groups:
- Resected pancreatic adenocarcinoma
- Locally advanced pancreatic cancer
- Metastatic pancreatic cancer
- Recurrent pancreatic cancer
- Endocrine pancreatic cancer
- Symptomatic patients with a negative diagnosis of pancreatic cancer
- Asymptomatic patients who had incidental findings of a pancreatic cancer identified by abdominal imaging discovered during a work-up for a different medical problem
- Heriditary pancreatic cancer
- Pancreatic intraepithelial neoplasia, intraductal papillary mucinous neoplasms, or mucinous cystic neoplasms
- Choledocholithiasis, cholelithiasis
- Chronic pancreatitis
- Frozen serum at -80C
- Demographic, diagnostic and medical data
- Stage (TNM, grade)
- Treatment History
BOU-1
Breast Cancer Stage IV
FFPE Blocks
Retrospective
More than 360 subjects
- 50% Progesterone Receptor-Positive
- 50% Progesterone Receptor-Negative
- Stage IV Breast Cancer
- Demographic, diagnostic data
- TNM
- Sample collection date
- Cold ischemia time
- ER and Her2 status
BOU-2
Breast Cancer
FFPE Blocks and PBMC
Retrospective
More than 40 subjects
- Breast Adenocarcinoma
- Peripheral Blood Mononuclear cells (PBMC), if available
- Primary tumor tissue only
- PBMC isolated from 10 mL of blood collected at diagnosis
- Age, ethnicity
- Sample collection date
- Date of diagnosis
- Confirmed clinical diagnosis
- Type of treatment
- Medical Outcome (presence/absence of relapse or death) within 5 years
BOU-3
Breast Cancer
FFPE Blocks
Retrospective
More than 10 subjects
- Triple-Negative Breast Cancer
Primary tumor tissue only 2 FFPE blocks:
- One pre-chemotherapy
- One post-chemotherapy
- Demographic, diagnostic data
- TNM
- Sample collection date
- Treatment history and overall survival data
BOU-4
Breast Cancer
FFPE Blocks
Retrospective
More than 20 subjects
- Invasive Breast Cancer Any stage, Grade 1 or 2
- Tissue biopsies
- Demographic, diagnostic data
- TNM
- Sample collection date
BOU-5
Breast Cancer
Fresh Frozen Tissue
Prospective
More than 12 subjects
- Triple-Negative Breast Cancer (TNBC)
- Any stage
- Age, ethnicity
- Height, weight
- Current treatment
- Concurrent diseases
- Pathology Report
BOU-6
Breast Cancer
Fresh Frozen Lymph Nodes
Retrospective
More than 270 subjects
3 groups:
- Breast Cancer
- Colorectal Cancer
- Gastric Cancer
- Lymph node weight > 50 mg
- Demographic, diagnostic data
- TNM
- Sample collection date
- Lymph Node weight
BOU-7
Breast Cancer
Whole Blood
Prospective
More than 30 subjects
3 groups:
- Breast Cancer
- Gastric Cancer
- Control (Healthy) Subjects
- Subjects with stage III or IV cancer
- Blood collected at time of diagnosis prior to any treatment or between treatment cycles
- Whole blood samples must be collected on specific Tubes
- Age, gender, ethnicity
- Sample collection date
- Date of diagnosis
- Confirmed clinical diagnosis
BOU-8
Ovarian Cancer Cervical Cancer
FFPE Blocks
Retrospective
More than 6 subjects
2 groups:
- 50% Ovarian Transitional Carcinoma
- 50% Cervical Small Cell Carcinoma
- Any stage
- Demographic, diagnostic data
- TNM
- Sample collection date
BOU-9
Ovarian Cancer
Fresh Tissue
Prospective
More than 4 subjects with Primary Ovarian Cancer
- Freshly resected tissue
- Any subtype
- Samples must be received fresh within 24 hours of resection
- Demographic, diagnostic data
- TNM
- Sample collection date
- Treatment History
BOU-10
Ovarian Cancer
Serum
Retrospective
More than 160 subjects
4 groups:
- Non-Cancerous Ovarian Disease
- Early Stage Ovarian Cancer (Stage I)
- Aggressive Ovarian Cancer (Stage III or IV) with a survival less than 5 years from diagnosis
- Non-Aggressive Ovarian Cancer (Stage III or IV) with a survival more than 5 years from diagnosis.
- Samples stored at -80oC
- No freeze-thaw cycle
- Demographic, diagnostic data
- TNM
- Sample collection date
- Treatment History
PT-1
Prostate Cancer
FFPE Blocks
Retrospective
More than 150 subjects
5 groups:
- PrCa patients without recurrence for a minimum of 5 years and who underwent radical prostatectomy and who didn’t receive adjuvant therapy
- PrCa patients with recurrence (within 3 years) and hormone refractory
- PrCa patients with recurrence (within 3 years) and hormone sensitive.
- PrCa patients who underwent transurethral resection of the prostate
- PrCa patients with metastasis. Hormone refractory
- Caucasian patients only
- Demographic, diagnostic and medical data
- Stage (TNM, grade)
- Treatment History and medical out-come
- Date of diagnosis
- PSA at diagnosis
- PSA after RPE
- Date of any PSA increase
PT-2
Prostate Cancer
FFPE Blocks
Retrospective
More than 20 subjects Advanced Stage:
- > or equal to T2 if Gleason score is 8-10
- > or equal to T3 if Gleason score is > or equal to 7
- 2 prostate tissue blocks per subject:
- Primary tumor and matched metastatic sites
- Demographic, diagnostic and medical data
- Stage (TNM, grade)
PT-3
Prostate Cancer
Freshly Resected Tumor Material
Prospective
More than 10 subjects
- Metastatic castrate-resistant PrCa (CRPC)
- Sample size: 2 g
- Samples must be received fresh within 24 hour of resection
- Age, Ethnicity
- Sample collection date
- Tumor Grade and Stage
- Treatment history
PT-4
Prostate Cancer
Plasma and Tumor Biopsy Samples
Retrospective
More than 120 subjects
3 groups:
- PrCa patients: positive biopsy
- Patients: negative biopsy
- Healthy male controls: only plasma samples
- Age-matched groups
- Demographic, diagnostic and medical data
- Stage (TNM, grade)
- Gleason score
- PSA value
PT-5
Prostate Cancer and Benign Prostate Hyperplasia
Serum
Retrospective
More than 400 subjects
2 groups:
- Submitted to prostate biopsy and diagnosed with PrCa
- Submitted to prostate biopsy and diagnosed with Benign Prostate Hyperplasia
- PSA between 2-10 ng/ml
- No prior biopsy within 5 years
- No prior prostate surgery
- Negative (non-suspicious) Digital Rectal Exam (DRE)
- Blood samples taken before prostate biopsy
- Samples stored at -80°C
- No Hemolytic samples
- No Samples with multiple freeze thaw cycles
- Demographic, diagnostic and medical data
- Sample collection date
- PSA value
- Diagnosis at biopsy
- Positive prostate biopsy: Biopsy Gleason grade
PT-6
Castration-Resistant Prostate Cancer
Whole Blood
Prospective
More than 30 subjects
- PSA level > 0.2 ng/ml and rising that is documented
- Blood samples collected in specific RNA Tubes
- Demographic data
- Treatment History and medical out-come
- Treatment history
- Radiographic progression to confirm CRPC
- Gleason Score
- PSA velocity
PT-7
Prostate Cancer
Urine
Prospective
More than 18 subjects
- Subjects with suspected PrCa (on the basis of abnormal PSA, urinary symptoms, family history of PrCa)
- Untreated subjects only
- No Digital Rectal Exam performed within the last 4 hours preceding specimen collection
- Samples stored at -80°C
- Age, ethnicity
- Date of diagnosis
- Data confirming diagnosis
- PSA value
BL-1
Urothelial Cell Carcinoma of the Bladder
Fresh Frozen Tissue
Retrospective
More than 150 subjects
6 groups:
- Ta low grade tumors
- Ta high grade tumors
- T1 high grade tumors
- T2 tumors
- T3 tumors
- T4 tumors
- Minimum of 20 mg of tiissue
- Demographic, diagnostic and medical data
- smoking status
- Clinical history
- Stage
- Treatment History and medical out-come
BL-2
Urothelial Cell Carcinoma of the Bladder
Tissue Micro-Arrays
Retrospective
More than 200 subjects
- Transitional cell carcinomas of the bladder
- Including Papillary carcinoma, Papillary urothelial neoplasms and Insitu carcinoma
- Caucasian patients only
- Diagnosis biopsy or post-treatment biopsy
- Surgery (partial or radical cystectomy)
- Primary tumors or metastases
- Demographic, diagnostic and medical data
- Stage (TNM, grade)
- Treatment History (Surgery, Chemotherapy, Biological therapy, Radiation therapy)
- Medical out-come (2 years)
BL-3
Urothelial Cell Carcinoma of the Bladder
Peripheral Blood Mononuclear Cells
Prospective
More than 25 subjects
- Advanced stage/higher grade
- Patients with invasive tumors only
- Several vials per subject
- Demographic, diagnostic and medical data
- Stage (TNM, grade)
- Treatment History
- HLA-typing
BL-4
Urothelial Cell Carcinoma of the Bladder
FFPE Blocks
Retrospective
More than 40 subjects:
2 Groups:
- Invasive cases
- Non-invasive cases (T1, Ta or Tcis)
- FFPE blocks must allow the cutting of > 50 sections
- Demographic, diagnostic and medical data
- Stage (TNM, grade)
- Treatment History
BL-5
Urothelial Cell Carcinoma of the Bladder
Freshly Resected Tumor Material
Prospective
More than 10 subjects
2 groups:
- Transitional cell carcinoma
- Epithelial Bladder Cancer
- Samples must be received fresh within 24 hour of resection
- Age, Gender, Ethnicity
- Tumor Grade and Stage
- Treatment history (if available)
- Sample collection date
BL-6
Urothelial Cell Carcinoma of the Bladder
FFPE Blocks
Retrospective
More than 20 subjects
- Stage III or IV, metastatic or surgically unresectable urothelial carcinoma
- Primary tumors only
- Any grade
- Tissue Samples fixed in 10% Neutral Buffered Formalin (NBF)
- FFPE blocks should allow the cutting of >50 sections
- Demographic, diagnostic data
- Stage (TNM, grade)
- Sample collection date
- Histological or cytological evidence of metastatic or surgically unresectalable transitional cell carcinoma
BL-7
Urothelial Cell Carcinoma
FFPE Blocks
Retrospective
More than 160 subjects 3 groups:
- Non-invasive (stage T1, Ta, Tis)
- Invasive (stage T2 or higher)
- Stage III or IV, metastatic/unresectable
- Diagnosed with Urothelial Cell Carcinoma
- Age, Gender, Ethnicity
- Sample collection date
- Pathological diagnosis
- Medical history
SK-1
Melanoma
Flash Frozen Tissue
Retrospective
More than 40 Subjects
2 Groups:
- Patients with more than 12 months survival
- Patients with less than 12 months survival
- Patients not treated by immunotherapy
- Age, gender, ethnicity
- Clinical history including disease-free survival, 5 years overall survival (if not deceased)
- Treatment
- Pathology diagnosis
SK-2
Melanoma
Serum
Retrospective
More than 100 Subjects
3 groups:
- Group 1 (n=50): Melanoma subjects with a uniform distribution in gender, age, ethnicity, type of melanoma and cancer staging
- Group 2 (n=30): Patients with benign skin conditions (moles, spitz nevus, seborrheic keratosis) with minimal bias in distribution in gender, age, and ethnicity from group 1 (and no other skin cancer)
- Group 3 (n=30): Patients without any skin condition, with minimal bias in distribution in gender, age and ethnicity from group 1
- Samples collected before any treatment or surgery specific to a skin condition
- Frozen samples
- Age, gender
- Sample collection date
- Date of diagnosis
- Confirmed diagnosis
- TNM staging
PED-1
Pediatric Cancer
FFPE Blocks
Retrospective
More than 20 subjects
12 groups:
- Lymphoma
- Osteosarcoma
- Ewing Sarcoma
- Rhabdomyosarcoma
- Neuroblastoma
- Wilms Tumors
- Medullary thyroid carcinoma
- Hepatoblastoma
- Retinoblastoma
- Hepatoblastoma
- Pancreatoblastoma
- Colorectal carcinoma
- Tissues must have been collected at diagnosis
- Age, gender
- Sample collection date
- Confirmation of pathological diagnosis
- Date of initial diagnosis
- Age, gender
- Sample collection date
- Confirmation of pathological diagnosis
- Date of initial diagnosis
PED-2
‘’Healthy” Pediatric Subjects
Fresh Whole Blood
Retrospective
More than 25 subjects
- Different age groups: 1, 3, 6, 9, and 12 months
- Whole blood collected by venous sampling in 3 different types of tubes
- Age
- Weight
- Gender
PED-3
Liver Cancer
FFPE Blocks
Retrospective
More than 30 subjects
- Pediatric Hepatoblastoma
- Subjects with hepatocellular carcinoma and undifferentiated embryonal sarcoma of the liver
- Age, gender, ethnicity
- Sample collection date
- Tumor stage
- Treatment history
- Pathological diagnosis
PED-4
Leigh Syndrome
Plasma
Retrospective
More than 3 subjects
- Confirmed diagnosis of Leigh syndrome
- Multiple samples collected overtime from the same patient
- Age, gender, ethnicity
- Symptoms and diagnosis report
- Treatment history
LC-1
Non-Small Cell Lung Carcinoma
FFPE Blocks
Retrospective
More than 3500 subjects
- 6 FFPE sections for screening of a specific mutation
- The corresponding FFPE blocks should remain available until the selection of positive blocks is completed
- Demographic, diagnostic and medical data
- Stage (TNM, grade)
LC-2
Non-Small Cell Lung Carcinoma & Squamous Cell Lung Carcinoma
Tissue Microarrays (TMA)
Prospective
More than 1000 subjects
4 groups:
- 50% Squamous cell Lung Carcinoma
- 4 groups (one group per stage)
- 50% Primary Lung Adenocarcinoma
- 4 groups (one group per stage)
- SCLC and NSCLC primo diagnosis
- No Asian subjects
- Also 5 FFPE slices placed in Eppendorf tube and one stained slide defining the punched area
- Demographic, diagnostic and medical data
- Stage (TNM, grade), % tumor cells in sample
- Smoking status
- Clinical history including Disease-free survival, Overall survival
- IHC results
LC-3
Non-Small Cell Lung Cancer (ALK)
FFPE Blocks
Retrospective
More than 150 subjects
- NSCLC with positive Anaplastic Lymphoma Kinase (ALK+) rearrangements
- Several biobanks can participate with a minimum of 10 cases/biobank
- Demographic, diagnostic and medical data
- Stage (TNM, grade)
- Method used for determination of ALK positivity
LC-4
Non-Small Cell Lung Cancer (PD-L1)
Plasma
Prospective
More than 30 subjects
- Positive for FFPE PD-L1 expression assessed by ICH
- Demographic, diagnostic and medical data
- Stage (TNM, grade)
LC-5
Non-Small Cell Lung Cancer (PD-L1)
FFPE Blocks
Retrospective
More than 30 subjects
- PD-L1 expression assessed by ICH
- Demographic, diagnostic and medical data
- Stage (TNM, grade)
LC-6
Non-Small Cell Lung Cancer (ALK)
Whole Blood and Matched FFPE Blocks
Prospective
More than 40 subjects
- 20ml of whole blood
- The tissue and blood collection must have been done with a maximum of 1 month from each other
- Whole blood collected in 2 different types of tubes and shipped at room temperature
- Demographic, diagnostic and medical data
- Stage (TNM, grade)
- Treatment History
LC-7
Non-Small Cell Lung Cancer (EGFR)
FFPE Blocks
Prospective
More than 40 subjects
- Locally advanced or metastatic NSCLC – stage IIIB or IV treated by EGFR tyrosine kinase inhibitors
- Demographic, diagnostic and medical data
- Stage (TNM, grade)
- EGFR mutation status
- Treatment History and medical out-come
- Treatment response to EGFR tyrosine kinase inhibitors treatment
LC-8
Non-Small Cell Lung Cancer (EGFR)
FFPE Blocks
Retrospective
More than 50 subjects
- Primary tumor or metastasis
- Progression on prior first-line therapy with different EGFR tyrosine kinase inhibitors
- Tissue must have been obtained after progression.
- Demographic, diagnostic and medical data
- Stage (TNM, grade)
- Treatment History
- Mutation data (point mutation in Exons)
LC-9
Non-Small Cell Lung Cancer (EGFR)
Plasma
Prospective
More than 300 subjects
2 groups:
- Stage III and IV NSCLC with mutated EGFR
- Stage III and IV NSCLC non-smokers women and/or Asians
- EDTA plasma aliquoted in 5 Eppendorf tubes
- Demographic, diagnostic and medical data
- Stage (TNM, grade)
- Treatment History and medical out-come
- Alcohol and smoking history
LC-10
Non-Small Cell Lung Carcinoma
FFPE Block and PBMC
Retrospective
More than 50 subjects
- FFPE block and PBMC collected at diagnosis, before start of any treatment
- Demographic, diagnostic and medical data
- Stage (TNM, grade)
- Treatment History and medical out-come
- If available, biomarker status: cMET, PI3K, EGFR, PTEN, ALK, ROS1, BRAF, HER2, NRAS…
LC-11
Non-Small Cell Lung Carcinoma
FFPE Blocks
Retrospective
More than 100 subjects
- FFPE surgery resected tissue blocks
- Any stage
- Patients newly diagnosed and prior to treatment
- Demographic, diagnostic and medical data
- Stage (TNM, grade)
- Treatment History
- 5 years medical follow-up
LC-12
Non-Small Cell Lung Carcinoma
Whole Blood
Retrospective
More than 100 subjects
- Stage IV NSCLC subjects
- Only chemotherapy naïve donors
- Blood sample collected directly into specific tubes and transported at room Temperature (16-25OC)
- Demographic, diagnostic and medical data
- Stage (TNM, grade)
- Treatment History and medical out-come
LC-13
Non-Small Cell Lung Cancer
Serum
Retrospective
More than 300 subjects
10 groups
- Stage I NSCLC adenocarcinoma, smokers and survived < 5 years from diagnosis
- Stage I NSCLC adenocarcinoma, smokers and survived > 5 years from diagnosis
- Stage I NSCLC adenocarcinoma, never-smokers and survived < 5 years from diagnosis
- Stage I NSCLC adenocarcinoma, never-smokers who survived > 5 years from diagnosis
- Stage II NSCLC adenocarcinoma, smokers and survived < 5 years from diagnosis
- Stage II NSCLC adenocarcinoma, smokers and survived > 5 years from diagnosis
- Mesothelioma
- IPF, bronchiectasis, asthma or pulmonary tuberculosis
- SCLC
- Healthy control subjects.
- Collection within 1 month of confirmed diagnosis and prior to start of any drug treatment or surgery
- Must not have had drug treatment associated to pulmonary disease in the 3 months prior to sample collection
- Must not have had surgery associate with pulmonary disease
- Demographic, diagnostic and medical data
- Stage (TNM, grade)
- Treatment History and medical out-come
- Smoking habits
LC-14
Non-Small Cell Lung Cancer (KRAS)
FFPE Blocks
Retrospective
More than 35 subjects
- Known KRAS codon 12 and 13 mutation status
- Any NSCLC subtype, any stage
- Demographic, diagnostic and medical data
- Stage (TNM, grade)
- Method used to detect KRAS mutation
LC-15
Small Cell Lung Carcinoma
FFPE Blocks
Retrospective
More than 180 subjects
- Any stage
- Demographic, diagnostic and medical data
- Stage (TNM, grade)
LC-16
Mesothelioma
FFPE Blocks
Retrospective
More than 180 subjects
- Samples collected over the past 4 years
- Age, gender
- Date of sample collection
- Stage
OC-1
Uveal Melanoma
FFPE Blocks
Retrospective
More than 15 subjects
- Diagnosed with Uveal Melanoma
- Age, Gender, Ethnicity
- Sample collection date
- Tumor location and size
- Pathological diagnosis
OC-2
Parotid Gland Cancer
FFPE Blocks
Retrospective
More than 15 subjects
- Advanced and metastatic
- Age, Gender, Ethnicity
- Medical history
- Tumor location and size
- Pathological diagnosis
OC-3
Thyroid Cancer
FFPE and Matched Frozen Tissue
Retrospective
More than 10 subjects
- 50% Medullary carcinoma and 50% parafollicular hyperplasia
- Diagnosed with thyroid cancer
- Age, Gender, Ethnicity
- Sample collection date
- Pathological diagnosis
- Medical history
OC-4
Fallopian Tube Cancer
FFPE Blocks
Retrospective
More than 40 subjects
- Stage IIIB or higher
- Age, Gender, Ethnicity
- TNM
- Medical history
- Pathology diagnosis
OC-5
Pheochromocytoma
Plasma and Matched Frozen Tissue or FFPE
Retrospective
More than 50 subjects
2 groups:
- 50% subjects with benign pheochromocytoma
- 50% subjects with malignant pheochromocytoma
- Pre-surgery plasma samples only
- Ischemia time < 1 hour for tissue
- Age, Gender, Ethnicity
- Sample collection date
- Clinical data
- Treatment history
OC-6
Head & Neck Cancer
FFPE
Retrospective
More than 40 subjects
6 groups:
- Tongue
- Larynx
- Nasopharynx
- Oropharynx
- Tonsil
- Hypopharynx
- Squamous Cell Carcinoma
- Age, Gender, Ethnicity
- TNM
- Clinical data
- Pathology diagnosis
AD-1
Alzheimer’s Disease
Serum
Retrospective
More than 200 subjects
7 Groups:
- Mild AD, Moderate AD
- Mild Cognitive Disorder (MCI) (“AD Converter”)
- Mild Cognitive Disorder (“Stable MCI”)
- Lewy Body Dementia
- Frontotemporal Dementia
- Vascular Dementia
- Healthy Controls Retrospective
- Serum
- All demographic, and medical data
- MMSE and MOCA, scores
- CSF Amyloid-ß42, t-Tau, and p-Tau concentrations
AD-2
Alzheimer’s Disease
Plasma
Prospective
More than 100 subjects
4 Groups:
- Alzheimer’s Disease
- Frontal Temporal Lobe Dementia
- Dementia with Lewy Bodies
- Controls Prospective
- EDTA plasma
- All demographic, and medical data
- Imaging (PET Scan, MRI) • Cerebrospinal Fluid Tau levels
AD-3
Alzheimer’s Disease
Cerebrospinal Fluid
Retrospective
More than 300 subjects
Different CSF hTau A:
- 1-42 spanning the entire clinical range Retrospective
- Cerebrospinal fluid samples collected with strictly standardized protocol
- All demographic, and medical data • MMSE score
AD-4
Alzheimer’s Disease
Frozen Brain Tissue
Retrospective
More than 15 subjects
- Different pattern for density of alpha-synuclein, tau and amyloid Retrospective
- Frozen brain cortical tissue
- All demographic, and medical data
- MMSE
- Braak Stage
- Neuropathology report
AD-5
Alzheimer’s Disease
Frozen Brain Tissue
Retrospective
More than 40 subjects:
- Alzheimer’s Disease and age- and gender-matched controls
- Frozen brain frontal cortical tissue
- All demographic, and medical data
- MMSE
- Braak Stage
- Neuropathology report
PD-1
Parkinson’s Disease
Cerebrospinal Fluid
Retrospective
More than 30 subjects
3 groups:
- Parkinson’s Disease without dementia
- Parkinson’s Disease with dementia
- Age-matched Control s(“healthy”)
- Subjects with confirmed Alzheimer’s Disease are excluded
- Age, Gender, Ethnicity
- Sample collection date
- Date of diagnosis
- Treatment and medical history
PD-2
Parkinson’s Disease
Brain Frozen Tissue
Retrospective
More than 5 subjects
2 groups:
- Parkinson’s Disease
- Age-matched control (“healthy”)
- Brain Temporal Cortical Frozen tissue
- All samples have histologically confirmed Lewy Body pathology
- Age, Gender, Ethnicity
- Clinical and neuropathological diagnosis
- Clinical History
- PMI
PD-3
Parkinson’s Disease
Brain FFPE Slides
Retrospective
More than 150 subjects
- Subjects with leucine-rich repeat kinase 2 (LRRK2) G2019S mutation
- Brain Tissue Sub-Regions:
- Dorsolateral Prefrontal Cortex
- Dorsolateral Amygdala
- Dorsolateral Putamen
- Age, Gender, Ethnicity
- Clinical and neuropathological diagnosis
TBI-1
Traumatic Brain Injury
Plasma
Prospective
More than 250 subjects
- Glasgow Coma Scale Score between 3 to 15
- Up to 4 samples collected per subject at different time points after head injury within:
- 0-3 hours
- 8-12 hours
- 24-48 hours
- 48-72 hours
- Age, Gender, Ethnicity
- Date/Time of initial presentation or injury
- Cause of TBI
- Other traumatic injuries
- Date/Time of blood collection
- GCS score at admission
MS-1
Multiple Sclerosis
Plasma
Retrospective
More than 30 subjects
2 groups:
- Patients who had an attack within 12 months after treatment initiation
- Patients without an additional attack and without significant (over 5) new T1/FLAIR lesions in the brain
- Treated subjects only
- Age, gender, ethnicity
- Duration of the disease
MS-2
Multiple Sclerosis
Frozen Brain Tissue
Retrospective
More than 2 subjects
- Brain tissue regions:
- Occipital Cortex
- Cerebellum
- Pons
- Temporal Lobe
- Basal Ganglia
- Parietal Lobe
- Frontal Cortex
- White Matter
- Cervical Cord
- Age, gender, ethnicity
- Duration of the disease
- PMI
HS-1
Healthy
Whole Blood and Matched Urine
Prospective
More than 120 subjects
3 groups:
- Aged between 30 and 39 years
- Aged between 40 and 59 years
- Aged between 60 and 80 years
- Donors with any clinical apparent symptoms
- Donors under any medication are excluded
- HIV, HCV, HBV seronegative
- Blood (more than 70ml) collected in different types of tubes at baseline, after 1 month, after 3 months
- Age, Gender, Ethnicity
- Laboratory results for complete blood count, coagulation parameters, clinical biochemistry and urinalysis:
HS-2
Healthy
Peripheral Blood Mononuclear Cells
Prospective
More than 10 subjects
- PBMCs should be frozen in at least 10 aliquots
- Age, Gender, Ethnicity
- Sample collection date
- PBMC count
HS-3
Healthy
Whole Blood
Prospective
At least 6 subjects
- 50% Male subjects, age-matched
- 50% Female subjects, age-matched
- Collected in specific Blood DNA Tubes
- Samples stored at +4°C right after blood collection
- Samples must be shipped and received within 3 days after blood draw
- Age, Gender, Ethnicity • Sample collection date
HS-4
Healthy
Liver FFPE Blocks
Retrospective
At least 12 subjects
- No malignancy
- No steatosis
- No inflammation
- Age
- Sample collection date
- Cause of death
- PMI
HS-5
Healthy
Cardiac FFPE and Frozen Tissue
Retrospective
At least 3 subjects
- Tissue from healthy human left cardiac ventricle
- Short PMI
- Age, Gender, Ethnicity
- Sample collection date
- Cause of death
- Clinical history
- PMI
INF-1
Hepatitis B
Serum
Retrospective
More than 400 subjects
4 groups:
- Genotype A
- Genotype C
- Genotype E
- Genotype F
- Patients infected with hepatitis B Virus (HBV), acute or chronic active
- Samples stored at -20°C
- Age, gender, ethnicity
- Country of Origin • Sample collection date
- Serology
INF-2
HIV and Hepatitis
Frozen EDTA Blood and EDTA Plasma
Prospective
More than 160 subjects
4 groups:
- HIV-1
- HIV-2
- Hepatitis B (HBV)
- Hepatitis C (HCV)
- Subjects with confirmed diagnosis with HIV-1 or HIV-2 or HBV or HCV
- Frozen samples stored at -80°C
- Age, gender, ethnicity
- Confirmation of diagnosis
- Genotype and subtype
INF-3
Human T-Lymphotropic Virus 1 (HTLV-1)
Frozen Serum
Retrospective
More than 80 subjects
- Healthy or diseased subjects seropositive for Human Y-lymphotropic virus 1 (HTLV-1)
- Samples stored at -20°C
- Age, gender
- Sample collection date
- Clinical history
INF-4
Human Papilloma Virus (HPV)
Cervical Cytology Samples
Retrospective
More than 120 subjects
4 groups:
- HPV-positive, low grade
- HPV-positive, high grade
- HPV-negative
- Cervical cancer
- Diagnosis of HPV infection or of cervical cancer
- Age, ethnicity
- Confirmation of diagnosis
- HPV data and information
INF-5
Brucellosis
Serum
Prospective
10 subjects
- Subjects with confirmed brucellosis
- Seropositive for brucellosis
- Age, gender, ethnicity
- Confirmation of diagnosis
- Serological test result
- Type of test used
INF-6
Parasitic Diseases
Stool
Retrospective
More than 80 subjects
- Infections due to human parasites
- Giardia
- Cryptosporidium
- Cyclospora, E. histolytical/dispar
- Hookworm
- Strongloides
- Ascaris
- Dientamoeba fragilis
- Blastocystis hominis
- E. nana…
- Samples must be placed in a specific preservative
- Results
INF-7
Tuberculosis
Lung FFPE Blocks
Retrospective
At least 10 subjects
- Acid Fast Bacillus positive
- Age, gender
- Sample collection date
- Pathological diagnosis
ID1408
Meningitis
RA-1
Rheumatoid Arthritis
Serum
Retrospective
More than 70 subjects
- Diagnosis of RA more than 1 year
- Collections at multiple time points including baseline, and multiple serial collections for a minimum of 2yrs
- Age, gender, ethnicity
- Disease activity assessment (DAS28)
- Health assessment questionnaire
- Radiographic assessment (VdH Score)
- CRP, CCP, and RF
RA-2
Rheumatoid Arthritis
Serum
Prospective
More than 200 subjects
4 groups:
- Rheumatoid Arthritis
- Psoriatic Arthritis
- Ankylosing Spondylitis
- Dermatomyositis
- Several aliquots
- Age, gender, ethnicity
- Medical history
- Treatment history
- Clinical outcome
PS-1
Psoriasis
Fresh Skin Biopsies
Prospective
More than 20 subjects
- 3 biopsies per subject from inflamed site
- Samples shipped immediately after collection at 4°C
- Age, gender, ethnicity
- Clinical history
- Concomitant treatment
PS-2
Psoriasis
Skin FFPE
Retrospective
More than 20 subjects
2 groups:
- Psoriasis
- Hidradenitis
- Skin Fistulae, Sinus or Fissure tissue blocks
- Fistulising/Sinus-Forming Dermatological Disease
- Age, gender, ethnicity
- Concurrent therapies known, including date of last anti-TNF dose
CD-1
Crohn’s Disease
Frozen Intestinal Tissue
Prospective
More than 30 Subjects
- For each subject: Resections or biopsies of fibrotic tissues and of normal adjacent tissue
- Age, gender, ethnicity
- Clinical history
- Clinical data regarding IBD
CD-2
Crohn’s Disease
Peripheral Blood Mononuclear Cells
Retrospective
More than 24 subjects:
3 groups:
- Crohn’s Disease
- Ulcerative Colitis
- Matched Healthy Controls
- PBMCs from subjects with active disease and/or in remission
- Age, gender, ethnicity
- Date of collection
- Disease activity at time of collection
- Treatment history
LE-1
Systemic Lupus Erythematosus
Kidney FFPE Tissue Blocks
Retrospective
More than 30 subjects with Lupus Nephritis
3 groups:
- No interstitial inflammation
- Mild interstitial inflammation
- Moderate/severe interstitial inflammation
- Kidney biospecimen (biopsies and/or samples from autopsy)
- Specimen collected within 2 years of initial diagnosis of SLE
- Age, gender, ethnicity
- Clinical diagnosis
- WHO classification for SLE
- Age of patient at biopsy or sample collection
- Pathology report
LE-2
Systemic Lupus Erythematosus
Plasma and matched Urine
Prospective
More than 50 subjects
3 groups:
- SLE
- Lupus nephritis
- Matched Healthy controls
- Subjects diagnosed with SLE with SLE Disease Activity Index (SLEDAI) > 6 and anti-nuclear antibodies (ANA) > 80
- Subjects diagnosed with LN by biopsy
- Age, gender, ethnicity
- Confirmation of diagnosis
SS-1
Primary Sjögren’s Syndrome
Saliva and Tears
Prospective
More than 50
6 subjects
2 groups:
- Local and systemic Primary Sjögren’s Syndrome
- Matched control subjects
- Whole saliva and parotid saliva
- Moderate, stable disease
- Tears collected using Schirmer strips
- Age, gender, ethnicity
- Medication
- Clinical data
TR-1
Heart and Renal Transplant Rejection
RNA and Plasma
Prospective
More than 80 Subjects
4 groups:
- Acute heart rejection as confirmed by endomyocardial biopsy
- No heart rejection as confirmed by endomyocardial biopsy
- Acute kidney rejection as confirmed by kidney biopsy with a Banff grade > 1
- No kidney rejection as confirmed by kidney biopsy
- Frozen EDTA Plasma and Isolated RNA
- Age, gender, ethnicity
- Treatment history
- Time duration between post-transplant biopsy and blood sample collection
CLD-1
Celiac Disease
Serum
Retrospective
More than 120 subjects
- Celiac Disease (non gluten-free diet, biopsy positive)
- Age, gender, ethnicity
- Clinical diagnosis of Celiac Disease biopsy report
- Serological test results
AL-1
Allergy
Serum
Retrospective
More than 25 subjects
- Tomato Lyc e 2 allergen
- Age, gender, ethnicity
- IgE
OD-1
Atopic Dermatitis
Fresh Skin Tissues
Retrospective
More than 10 subjects
- Skin punch biopsies
- A diagnosis with moderate to severe AD
- Samples delivered in tissue culture media within 24 hours at +4°C
- Age, gender, ethnicity
- Concurrent disorders
- Date of sample collection
- Medical treatment history
OD-2
Diabetes Mellitus
Frozen Liver and Spleen tissues
Retrospective
More than 15 subjects
2 groups:
- Diabetes Type I
- Control, non-diabetic, subjects
- Subjects between 30 to 65 years
- Age, gender, ethnicity
- Weight
- Medical history
OD-3
Progressive Supranuclear Palsy
Frozen Brain Tissue
Retrospective
More than 2 subjects
- Caudate Nucleus
- Putamen
- Globus Pallidus
- Diagnosis of PSP confirmed by immunohistochemistry using anti-tau antibodies
- Age, gender, ethnicity
- Medical history
- Confirmed diagnosis (anti-Tau ICH results)
- PMI
OD-4
Barrett's Esophagus
Esophagus FFPE Tissue Blocks
Retrospective
More than 15 subjects
- Esophagus tissue
- Tissue from resections or biopsies
- Age, gender, ethnicity
- Medical history
- Treatment history
OD-5
Idiopathic Pulmonary Fibrosis
FFPE and Frozen Lung Tissue Blocks and Serum
Prospective
More than 18 subjects
- Lung tissues samples from resections, biopsies, or autopsy
- IPF diagnosed with lung biopsy and/or High Resolution Computed Tomography (HCRT)
- Age, gender, ethnicity
- Pathology report
- Clinical Diagnosis method (e.g. HCRT or biopsy/autopsy)
- Medical history
- Treatment history
OD-6
Fatty Liver or Non- Alcoholic Steatohepatitis
Liver FFPE slides and Plasma
Retrospective
More than 20 subjects
2 groups:
- NASH with mild fibrosis
- NASH with moderate fibrosis
- NAFLD fibrosis score
- Age, gender, ethnicity
- Duration of the disease
- Medical history
OD-7
Hypertrophic Cardiomyopathy
Whole Blood
Prospective
More than 200 subjects
- Diagnosed with Hypertrophic Cardiomyopathy
- Age, gender, ethnicity
- Treatment history
- Disease-causing genetic mutation information
GD-1
Muscular Dystrophy
Frozen Muscular Tissue and Matched Serum
Retrospective
More than 10 subjects
- Dysferlinopathy and Miyoshi Myopathy
- Age, gender, ethnicity
- Sample collection date
- Date of diagnosis
- Clinical data
GD-2
Leigh syndrome
Plasma
Retrospective
More than 12 subjects
- Confirmed diagnosis with Leigh Disease
- Age, gender, ethnicity
- Symptoms and diagnosis report
- Medical history
- Medical follow-up
- Treatment history
- Type of mutations
GD-3
Fabry Disease
Plasma
Retrospective
More than 50 subjects
- Confirmed diagnosis with Fabry Disease
- Samples collected prior to Enzyme Replacement Therapy
- Age, gender, ethnicity
- Form of disease
- Medical history
- Treatment history
- Type of GLA mutation
GD-4
G6PD deficiency
Whole Blood
Prospective
More than 8 subjects
- G6PD status determined based on enzymatic activity of G6PD in the subject’s blood samples
- Age, gender, ethnicity
- Medical history
LB-1
Colorectal Cancer (KRAS)
Plasma and FFPE Blocks KRAS +
Prospective
More than 200 subjects
- Newly Diagnosed patients with Colorectal Cancer stage IV
- Blood samples collected before treatment
- 20 to 40 40 ml plasma
- Demographic, diagnostic and medical data
- Stage
- KRAS mutation status
LB-2
Non-Small Cell Lung Cancer (ALK)
Whole Blood and FFPE blocks Alk +
Prospective
More than 40 subjects
- Whole blood collected in different types of tubes and shipped at room temperature
- Demographic, diagnostic and medical data
- Stage (TNM, grade)
- Treatment History
LB-3
Non-Small Cell Lung Cancer (EGFR)
Plasma
Prospective
More than 200 subjects
- Stage III and IV NSCLC with mutated EGFR
- Stage III and IV NSCLC non-smokers women and/or Asians
- Plasma aliquoted
- Demographic, diagnostic and medical data
- Stage (TNM, grade)
- Treatment History and medical out-come
LB-4
Non-Small Cell Lung Cancer (PD-L1)
Plasma
Prospective
More than 30 subjects
- Positive for FFPE PD-L1 expression assessed by ICH
- Demographic, diagnostic and medical data
- Stage (TNM, grade)
LB-5
Gastric Cancer
PBMC and FFPE Blocks
Retrospective
More than 50 subjects
- Samples collected at diagnosis, before start of any treatment
- PBMC isolated from 10 mL of blood
- Demographic, diagnostic and medical data
- Stage (TNM, grade)
- Treatment History and medical out-come
- Biomarker status: EGFR, KRAS,
LB-6
Skin, Lung and Colorectal cancers (BRAFK, EGFR, KRAS)
Urine
Prospective
4 groups:
- Melanoma BRAF mutated
- NSCLC EGFR mutated Stage IV
- NSCLC KRAS mutated Stage IV
- Colorectal KRAS mutated
- Urine frozen at -80°C
- Demographic, diagnostic and medical data
- Stage
- Treatment History
- Date of tissue collection
- Date of urine sampling
BA-1
Troponin I
Plasma
Prospective
More than 200 subjects
8 groups:
- Below 0.10 ng/ ml
- 0.10-0.20 ng/ ml
- 0.20-0.5 ng/ ml
- 0.5-1.00 ng/ ml
- 1.00 -2.00 ng/ ml
- 2.00-5.00 ng/ ml
- 5.00-10.00 ng/ ml
- Above 10.0 ng/ ml
- 5 ml plasma collected according to sponsor protocol
- Age, gender
- Sample collection date
BA-2
Thyroid-Stimulating Hormone (TSH)
Plasma and Serum
Prospective
100 subjects
2 groups:
- Below 0.40 mIU/L
- Above 10 mIU/L
- 2ml aliquots
- Age, gender
- Sample collection date
BA-3
Procalcitonine
Serum
Retrospective
More than 130 subjects
5 groups:
- Below 0.5 ng/ ml
- 0.5-2.00 ng/ ml
- 2.00 -5.00 ng/ ml
- 5.00-10.00 ng/ ml
- Above 10.00 ng/ ml
- 1ml aliquots
- Age, gender
- Sample collection date
BA-4
Vitamin D 25(OH)D
Serum
Prospective
More than 100 subjects
4 groups:
- Below 20 ng/ ml
- 20-30 ng/ ml
- 30-50 ng/ ml
- Above 50 ng/ ml
- 5 ml serum
- Age , gender
- Sample collection date